<?xml version='1.0' encoding='utf-8'?>
<document id="22936637"><sentence text="Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats."><entity charOffset="53-65" id="DDI-PubMed.22936637.s1.e0" text="atorvastatin" /><entity charOffset="138-148" id="DDI-PubMed.22936637.s1.e1" text="cilostazol" /><pair ddi="false" e1="DDI-PubMed.22936637.s1.e0" e2="DDI-PubMed.22936637.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22936637.s1.e0" e2="DDI-PubMed.22936637.s1.e1" /></sentence><sentence text="Cilostazol (CLZ) and atorvastatin (ATV) are often co-prescribed to treat conditions such as peripheral arterial disease"><entity charOffset="0-10" id="DDI-PubMed.22936637.s2.e0" text="Cilostazol" /><entity charOffset="12-15" id="DDI-PubMed.22936637.s2.e1" text="CLZ" /><entity charOffset="21-33" id="DDI-PubMed.22936637.s2.e2" text="atorvastatin" /><entity charOffset="35-38" id="DDI-PubMed.22936637.s2.e3" text="ATV" /><pair ddi="false" e1="DDI-PubMed.22936637.s2.e0" e2="DDI-PubMed.22936637.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22936637.s2.e0" e2="DDI-PubMed.22936637.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22936637.s2.e0" e2="DDI-PubMed.22936637.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22936637.s2.e0" e2="DDI-PubMed.22936637.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22936637.s2.e1" e2="DDI-PubMed.22936637.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22936637.s2.e1" e2="DDI-PubMed.22936637.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22936637.s2.e1" e2="DDI-PubMed.22936637.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22936637.s2.e2" e2="DDI-PubMed.22936637.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22936637.s2.e2" e2="DDI-PubMed.22936637.s2.e3" /></sentence><sentence text=" In the present study, the drug-drug interaction potential of multi-dose ATV co-administration with CLZ on both pharmacokinetics and the anti-thrombotic property of CLZ is demonstrated"><entity charOffset="100-102" id="DDI-PubMed.22936637.s3.e0" text="CLZ" /><entity charOffset="165-167" id="DDI-PubMed.22936637.s3.e1" text="CLZ" /><entity charOffset="73-75" id="DDI-PubMed.22936637.s3.e2" text="ATV" /><pair ddi="false" e1="DDI-PubMed.22936637.s3.e2" e2="DDI-PubMed.22936637.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22936637.s3.e2" e2="DDI-PubMed.22936637.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22936637.s3.e2" e2="DDI-PubMed.22936637.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22936637.s3.e0" e2="DDI-PubMed.22936637.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22936637.s3.e0" e2="DDI-PubMed.22936637.s3.e1" /></sentence><sentence text=" The pharmacokinetic parameters of CLZ (6 mg/kg, twice daily) were determined in male Wistar rats after 7 days co-administration with ATV (5 mg/kg, once daily) in order to assess the interaction potential between CLZ and ATV on chronic treatment"><entity charOffset="35-37" id="DDI-PubMed.22936637.s4.e0" text="CLZ" /><entity charOffset="213-215" id="DDI-PubMed.22936637.s4.e1" text="CLZ" /><entity charOffset="134-136" id="DDI-PubMed.22936637.s4.e2" text="ATV" /><entity charOffset="221-223" id="DDI-PubMed.22936637.s4.e3" text="ATV" /><pair ddi="false" e1="DDI-PubMed.22936637.s4.e0" e2="DDI-PubMed.22936637.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22936637.s4.e0" e2="DDI-PubMed.22936637.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22936637.s4.e0" e2="DDI-PubMed.22936637.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22936637.s4.e0" e2="DDI-PubMed.22936637.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22936637.s4.e2" e2="DDI-PubMed.22936637.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22936637.s4.e2" e2="DDI-PubMed.22936637.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22936637.s4.e2" e2="DDI-PubMed.22936637.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22936637.s4.e1" e2="DDI-PubMed.22936637.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22936637.s4.e1" e2="DDI-PubMed.22936637.s4.e3" /></sentence><sentence text=" In vitro metabolic inhibition and everted gut sac studies were conducted to elucidate the mechanism of this interaction" /><sentence text=" Pharmacodynamic drug-drug interaction was evaluated on anti-thrombotic models including time to occlusion, platelet aggregation and rat tail bleeding time" /><sentence text=" A validated LC-MS/MS method was employed simultaneously to quantify both ATV and CLZ in rat plasma matrix"><entity charOffset="82-84" id="DDI-PubMed.22936637.s7.e0" text="CLZ" /><entity charOffset="74-76" id="DDI-PubMed.22936637.s7.e1" text="ATV" /><pair ddi="false" e1="DDI-PubMed.22936637.s7.e1" e2="DDI-PubMed.22936637.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22936637.s7.e1" e2="DDI-PubMed.22936637.s7.e0" /></sentence><sentence text=" A statistically significant increase in systemic exposure (Css(max) by ~1" /><sentence text="75 fold; AUC by ~3" /><sentence text="0 fold) to CLZ was observed in ATV pre-treated rats"><entity charOffset="11-13" id="DDI-PubMed.22936637.s10.e0" text="CLZ" /><entity charOffset="31-33" id="DDI-PubMed.22936637.s10.e1" text="ATV" /><pair ddi="false" e1="DDI-PubMed.22936637.s10.e0" e2="DDI-PubMed.22936637.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22936637.s10.e0" e2="DDI-PubMed.22936637.s10.e1" /></sentence><sentence text=" In vitro metabolism studies using liver microsomes (RLM and HLM) demonstrated statistically significant inhibition of CLZ metabolism when co-incubated with ATV"><entity charOffset="119-121" id="DDI-PubMed.22936637.s11.e0" text="CLZ" /><entity charOffset="157-159" id="DDI-PubMed.22936637.s11.e1" text="ATV" /><pair ddi="false" e1="DDI-PubMed.22936637.s11.e0" e2="DDI-PubMed.22936637.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22936637.s11.e0" e2="DDI-PubMed.22936637.s11.e1" /></sentence><sentence text=" No change in apparent permeability of CLZ was observed in the presence of ATV"><entity charOffset="39-41" id="DDI-PubMed.22936637.s12.e0" text="CLZ" /><entity charOffset="75-77" id="DDI-PubMed.22936637.s12.e1" text="ATV" /><pair ddi="false" e1="DDI-PubMed.22936637.s12.e0" e2="DDI-PubMed.22936637.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22936637.s12.e0" e2="DDI-PubMed.22936637.s12.e1" /></sentence><sentence text=" Atorvastatin showed a significant delay in artery occlusion time without altering CLZ's bleeding time and platelet aggregation profile"><entity charOffset="1-13" id="DDI-PubMed.22936637.s13.e0" text="Atorvastatin" /><entity charOffset="83-94" id="DDI-PubMed.22936637.s13.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.22936637.s13.e0" e2="DDI-PubMed.22936637.s13.e0" /><pair ddi="false" e1="DDI-PubMed.22936637.s13.e0" e2="DDI-PubMed.22936637.s13.e1" /></sentence><sentence text=" Collectively the results of these studies provide metabolic insight into the nature of drug-drug interaction between the selected drugs" /><sentence text=" Co-administration with ATV influences the pharmacokinetics and anti-thrombotic property of CLZ"><entity charOffset="92-94" id="DDI-PubMed.22936637.s15.e0" text="CLZ" /><entity charOffset="24-26" id="DDI-PubMed.22936637.s15.e1" text="ATV" /><pair ddi="false" e1="DDI-PubMed.22936637.s15.e1" e2="DDI-PubMed.22936637.s15.e1" /><pair ddi="false" e1="DDI-PubMed.22936637.s15.e1" e2="DDI-PubMed.22936637.s15.e0" /></sentence><sentence text=" A thorough clinical investigation is required before extrapolation of data to humans" /><sentence text="" /></document>